Enhanced gastrointestinal absorption of aluminumin in uremic rats

Ittel, T. H.; Buddington, Bruce; Miller, Norman F.; Alfrey, Allen C.

doi:10.1038/ki.1987.282

Cited by 58 publications

(16 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in contrast with the present study, in which no correlation between bone lanthanum levels and the development of a mineralization defect could be demonstrated. The slightly higher lanthanum concentrations in the bone of CRF animals might result from minor differences in gastrointestinal absorption of the element related to the CRF (49) and/or from higher bone turnover in the hyperparathyroid rat. Excretion of lanthanum is known to occur mainly via the bile (~63% of 0.3-mg/kg intravenous dose of LaCl 3 in NRF rats) and not the kidney (50) (Shire Pharmaceutical Development, unpublished results).…”

Section: Discussionmentioning

confidence: 99%

Does the Phosphate Binder Lanthanum Carbonate Affect Bone in Rats with Chronic Renal Failure?

Behets¹,

Dams²,

Vercauteren³

et al. 2004

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Abstract. Adequate control of phosphate levels remains an important issue in patients with chronic renal failure (CRF). Lanthanum carbonate has been proposed as a new phosphate binder. Previous studies have shown a high phosphate binding capacity (Ͼ97%) and low gastrointestinal absorption of lanthanum, without serious toxic side effects in the presence of a normal renal function (NRF). Because of lanthanum's physicochemical resemblance to calcium, the possible effects of it on bone have to be considered. The aim of this study was to investigate the effects of lanthanum carbonate on bone histology in NRF and CRF rats after oral administration of the compound with doses of 100, 500, or 1000 mg/kg per d for 12 wk. Bone histomorphometry showed that CRF animals that received vehicle developed secondary hyperparathyroidism. Urinalysis of lanthanum-loaded CRF animals showed a dosedependent decrease in urinary phosphorus excretion, which was clearly more pronounced in the CRF groups compared with NRF animals. Phosphatemia, however, remained normal. Lanthanum carbonate administration induced a dose-dependent decrease in bone formation rate and increase in osteoid area in CRF animals. Three of seven animals in the CRF-1000 group and one of eight animals in the NRF-100 group were classified as having a mineralization defect. The number of cuboidal osteoblasts, however, was not affected, indicating that bone changes were not due to a toxic effect of lanthanum on the osteoblast. Furthermore, lanthanum concentrations in the femur remained low and did not correlate with histomorphometric parameters. These findings suggest that the administration of high doses of phosphate binder (1000 mg/kg per d lanthanum carbonate), in combination with decreased 25-(OH) vitamin D 3 in the uremic state, resulted in phosphate depletion and followed by an increased mobilization of phosphorus out of bone and/or reduced incorporation into bone. There was no evidence that lanthanum had a direct toxic effect on osteoblasts.

show abstract

Section: Discussionmentioning

confidence: 99%

Does the Phosphate Binder Lanthanum Carbonate Affect Bone in Rats with Chronic Renal Failure?

Behets¹,

Dams²,

Vercauteren³

et al. 2004

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…The present study also found no significant increase in the Al content of the serum, liver, cerebral cortex, or femoral bone in Al(OH) 3 -treated rats when compared with the normal control rats despite 5 /6-nephrectomy . [24] . They orally administered A1C13 to rats with moderate to severe uremia and found no difference in the serum Al concentration between the rats with normal and reduced renal function, indicating that the remnant kidney eliminated Al to a nearly normal degree .…”

Section: Discussionmentioning

confidence: 95%

Sodium ferrous citrate does not cause aluminum retention in rats with experimentally induced renal failure

et al. 1995

View full text Add to dashboard Cite

Accumulation of aluminum (AI) in the brain Introduction and bone has been implicated in the development of encephalopathy and osteodystrophy in patients with renal failure, and it has been reported that citric acid enhances Al absorption and retention . Oral iron supplementation is usually carried out with recombinant human erythropoietin (rHuEPO) therapy in end-stage renal disease (ESRD) patients . Accordingly, there is a possibility that Ferromia (sodium ferrous citrate, tetrasodium biscitrato iron (11), E0708), which is used for the treatment of iron deficiency anemia, might accelerate Al absorption and retention . To investigate this possibility, we administered oral aluminum hydroxide [Al(OH)3] [ 50mgAl/kg body weight (BW)] with or without E0708 (48mg/kg BW or 480 mg/kg BW) to y/6-nephrectomized rats (n = 27) five times per week for 16 weeks, and determined the Al content of the serum, liver, cerebral cortex, and femoral bone by flameless atomic absorption spectroscopy . The low dose of E0708 corresponded approximately to the clinical dose, and its low and high doses contained 34 .5 mg/kgBW and 345 .Omg/kgBW, respectively, of citric acid. In addition, we gave 5 /a-nephrectomized rats Al(OH) 3 with citric acid at 35 mg/kg B W, which was identical to the citric acid dose of the low-dose regimen of E0708 . The weight gain, serum urea nitrogen, and creatinine levels indicated that the rats developed mild to moderate renal failure . There was no significant increase of the Al content in the serum or organs of the AI(OH) 3 + E0708-treated rats when compared with the AI(OH) 3 -treated rats and Al(OH) 3 + citric acid-treated rats . These findings suggest that the usual clinical dose of E0708 does not promote Al retention in rats with mild to moderate renal failure or normal rats .

show abstract

“…Normally, only small amounts of aluminum are absorbed in the gastrointestinal tract. However, an enhanced uptake of aluminum possibly due to low gastric pH, vitamin D depletion and iron deficiency, together with an impaired elimination is observed in renal failure [71, 72, 73, 74]. The ingestion of aluminum compounds together with citrate (e.g.…”

Section: The Many Faces Of Renal Osteodystrophymentioning

confidence: 99%

Renal Osteodystrophy: New Insights in Pathophysiology and Treatment Modalities with Special Emphasis on the Insulin-Like Growth Factor System

Jehle

Mohan

et al. 1998

Nephron

View full text Add to dashboard Cite

Enhanced gastrointestinal absorption of aluminumin in uremic rats

Cited by 58 publications

References 42 publications

Does the Phosphate Binder Lanthanum Carbonate Affect Bone in Rats with Chronic Renal Failure?

Does the Phosphate Binder Lanthanum Carbonate Affect Bone in Rats with Chronic Renal Failure?

Sodium ferrous citrate does not cause aluminum retention in rats with experimentally induced renal failure

Renal Osteodystrophy: New Insights in Pathophysiology and Treatment Modalities with Special Emphasis on the Insulin-Like Growth Factor System

Contact Info

Product

Resources

About